ResMed Statistics

Total Valuation

ResMed has a market cap or net worth of 37.50 billion. The enterprise value is 36.93 billion.

Market Cap	37.50B
Enterprise Value	36.93B

Important Dates

The next estimated earnings date is Thursday, April 23, 2026.

Earnings Date	Apr 23, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.43%
Shares Change (QoQ)	-0.36%
Owned by Insiders (%)	0.52%
Owned by Institutions (%)	74.53%
Float	144.79M

Valuation Ratios

The trailing PE ratio is 25.24 and the forward PE ratio is 22.14.

PE Ratio	25.24
Forward PE	22.14
PS Ratio	6.95
PB Ratio	5.93
P/TBV Ratio	13.17
P/FCF Ratio	20.93
P/OCF Ratio	19.59
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 17.86, with an EV/FCF ratio of 20.61.

EV / Earnings	24.85
EV / Sales	6.84
EV / EBITDA	17.86
EV / EBIT	19.96
EV / FCF	20.61

Financial Position

The company has a current ratio of 3.06, with a Debt / Equity ratio of 0.13.

Current Ratio	3.06
Quick Ratio	1.97
Debt / Equity	0.13
Debt / EBITDA	0.41
Debt / FCF	0.47
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 25.68% and return on invested capital (ROIC) is 26.60%.

Return on Equity (ROE)	25.68%
Return on Assets (ROA)	14.75%
Return on Invested Capital (ROIC)	26.60%
Return on Capital Employed (ROCE)	25.44%
Weighted Average Cost of Capital (WACC)	8.87%
Revenue Per Employee	509,257
Profits Per Employee	140,177
Employee Count	10,600
Asset Turnover	0.69
Inventory Turnover	2.15

Taxes

In the past 12 months, ResMed has paid 332.81 million in taxes.

Income Tax	332.81M
Effective Tax Rate	18.30%

Stock Price Statistics

The stock price has increased by +30.18% in the last 52 weeks. The beta is 0.88, so ResMed's price volatility has been lower than the market average.

Beta (5Y)	0.88
52-Week Price Change	+30.18%
50-Day Moving Average	24.61
200-Day Moving Average	20.98
Relative Strength Index (RSI)	52.52
Average Volume (20 Days)	10,577

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	9.69

Income Statement

In the last 12 months, ResMed had revenue of 5.40 billion and earned 1.49 billion in profits. Earnings per share was 10.11.

Revenue	5.40B
Gross Profit	3.32B
Operating Income	1.85B
Pretax Income	1.82B
Net Income	1.49B
EBITDA	2.02B
EBIT	1.85B
Earnings Per Share (EPS)	10.11

Full Income Statement

Balance Sheet

The company has 1.42 billion in cash and 847.72 million in debt, giving a net cash position of 569.35 million.

Cash & Cash Equivalents	1.42B
Total Debt	847.72M
Net Cash	569.35M
Net Cash Per Share	n/a
Equity (Book Value)	6.32B
Book Value Per Share	43.39
Working Capital	2.57B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 1.91 billion and capital expenditures -122.89 million, giving a free cash flow of 1.79 billion.

Operating Cash Flow	1.91B
Capital Expenditures	-122.89M
Free Cash Flow	1.79B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 61.47%, with operating and profit margins of 34.19% and 27.53%.

Gross Margin	61.47%
Operating Margin	34.19%
Pretax Margin	33.69%
Profit Margin	27.53%
EBITDA Margin	37.51%
EBIT Margin	34.19%
FCF Margin	33.19%

Dividends & Yields

ResMed does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	22.25%
Buyback Yield	0.43%
Shareholder Yield	0.43%
Earnings Yield	3.96%
FCF Yield	4.78%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

ResMed has an Altman Z-Score of 12.89 and a Piotroski F-Score of 6.

Altman Z-Score	12.89
Piotroski F-Score	6